Financial toxicity in thyroid cancer survivors.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
11
9
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Financial burden and distress are high in patients with thyroid cancer. However, little has been done to evaluate potential interventions to mitigate financial toxicity in survivors. This review will cover current data on the impact of financial toxicity on quality of life and clinical outcomes in patients with thyroid cancer and highlight areas for future study. Thyroid cancer incidence has nearly tripled in the past decades, and cost of treatment is predicted to rise more than other cancers over the next decade. With mean age of diagnosis at 51 years, most patients begin treatment while still working, do not qualify for Medicare or Social Security, and are susceptible to higher financial burden. Though thyroid cancer has high survival rates, some studies suggest patients have worse quality of life and higher financial burden than more morbid cancers. Thyroid cancer survivors have high rates of financial toxicity, and there remains need for longitudinal studies to evaluate how financial burden may change during the treatment process while also assessing potential tools to mitigate this burden.
Identifiants
pubmed: 37470486
doi: 10.1097/MED.0000000000000826
pii: 01266029-990000000-00068
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-243Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cancer Stat Facts: Thyroid Cancer. 2023. SEER. Available at: https://seer.cancer.gov/statfacts/html/thyro.html [Accessed 3 June 2023].
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics. CA Cancer J Clin 2023; 73:17–48.
Kitahara CM, Schneider AB. Epidemiology of thyroid cancer. Cancer Epidemiol Biomarkers Prev 2022; 31:1284–1297.
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016; 388:2783–2795.
Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 2013; 27:80–81. 149.
Hussaini SMQ, Gupta A, Dusetzina SB. Financial toxicity of cancer treatment. JAMA Oncol 2022; 8:788.
Banthin JS, Bernard DM. Changes in financial burdens for healthcare: national estimates for the population younger than 65 years, 1996 to 2003. JAMA 2006; 296:2712–2719.
NHE Fact Sheet. Centers for Medicare & Medicaid Services. 2023. Available at: https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet [Accessed 2 June 2023].
Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020; 29:1304–1312.
Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 2014; 10:332–338.
Han X, Robinson LA, Jensen RE, et al. Factors associated with health-related quality of life among cancer survivors in the United States. JNCI Cancer Spectr 2021; 5:pkaa123.
Yousuf Zafar S, Mcneil RB, Thomas CM, et al. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract 2015; 11:145–150.
Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 2016; 122:1283–1289.
Kang D, Bae KR, Lim J, et al. Impact of objective financial burden and subjective financial distress on spiritual well being and quality of life among working-age cancer survivors. Support Care Cancer 2022; 30:4917–4926.
Pangestu S, Rencz F. Comprehensive score for financial toxicity and health-related quality of life in patients with cancer and survivors: a systematic review and meta-analysis. Value Health 2023; 26:300–316.
Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 2016; 109:djw205.
Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw 2019; 17:1184–1192.
Yabroff KR, Mariotto A, Tangka F, et al. Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care. J Natl Cancer Inst 2021; 113:1670–1682.
Nelson B. A growing side effect of cancer care: financial toxicity: researchers are taking a closer look at the financial ruin and other disastrous consequences that can accompany escalating costs of cancer care. Cancer Cytopathol 2019; 127:673–674.
Gilligan AM, Alberts DS, Roe DJ, et al. Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am J Med 2018; 131:1187–1199. e5.
Zafar SY. Financial toxicity of cancer care: it's time to intervene. J Natl Cancer Inst 2015; 108:djv370.
Honda K, Gyawali B, Ando M, et al. A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. Ecancermedicalscience 2018; 12:847.
Shankaran V, Li L, Fedorenko C, et al. Risk of adverse financial events in patients with cancer: evidence from a novel linkage between cancer registry and credit records. J Clin Oncol 2022; 40:884–891.
Abrams HR, Durbin S, Huang CX, et al. Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med 2021; 11:2043–2054.
Gordon LG, Merollini KMD, Lowe A, et al. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient 2017; 10:295–309.
Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff 2013; 32:1143–1152.
Zajacova A, Dowd JB, Schoeni RF, et al. Employment and income losses among cancer survivors: estimates from a national longitudinal survey of American families. Cancer 2015; 121:4425–4432.
Banegas MP, Guy GP, de Moor JS, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff 2016; 35:54–61.
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016; 34:980–986.
De Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014; 120:3245–3253.
de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017; 123:476–484.
Lathan CS, Cronin A, Tucker-Seeley R, et al. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 2016; 34:1732–1740.
Inguva S, Priyadarshini M, Shah R, et al. Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA. Future Oncol 2022; 18:1569–1581.
Benedict C, Fisher S, Schapira L, et al. Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. Psychooncology 2022; 31:9–20.
Barton MK. Bankruptcy linked to early mortality in patients with cancer. CA Cancer J Clin 2016; 66:267–268.
Hastert TA, Young GS, Pennell ML, et al. Financial burden among older, long-term cancer survivors: results from the LILAC study. Cancer Med 2018; 7:4261–4272.
Jiang JM, Eichler J, Bodner W, et al. Predictors of financial toxicity in patients receiving concurrent radiation therapy and chemotherapy. Adv Radiat Oncol 2022; 8:101141.
Han X, Zhao J, Zheng Z, et al. Medical financial hardship intensity and financial sacrifice associated with cancer in the United States. Cancer Epidemiol Biomarkers Prev 2020; 29:308–317.
Chen DW, Reyes-Gastelum D, Veenstra CM, et al. Financial hardship among hispanic women with thyroid cancer. Thyroid 2021; 31:752–759.
Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018; 68:153–165.
Lentz R, Benson AB, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol 2019; 120:85–92.
Shankaran V, Jolly S, Blough D, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012; 30:1608–1614.
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18:381–390.
Wu J, Moss H. Financial toxicity in the post-health reform era. J Am Coll Radiol 2023; 20:10–17.
Aviki EM, Manning-Geist BL, Sokolowski SS, et al. Risk factors for financial toxicity in patients with gynecologic cancer. Am J Obstet Gynecol 2022; 226:817.e1–817.e9.
Khera N. Reporting and grading financial toxicity. J Clin Oncol 2014; 32:3337–3339.
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74:2913–2921.
Uppal N, Collins R, James B. Thyroid nodules: global, economic, and personal burdens. Front Endocrinol (Lausanne) 2023; 14:1113977.
Lubitz CC, Kong CY, McMahon PM, et al. Annual financial impact of well differentiated thyroid cancer care in the United States. Cancer 2014; 120:1345–1352.
Zheng F, Huang Y, Wright J, et al. Out-of-pocket costs for patients undergoing thyroid surgery. Ann Surg 2022; 276:E937–E943.
Bhattacharjee S, Khobrani M, Alrabiah Z, et al. Healthcare expenditures among community-dwelling adults with thyroid cancer in the United States: a propensity score matched analysis. Heliyon 2019; 5:e01995.
Sahli ZT, Zhou S, Sharma AK, et al. Rising cost of thyroid surgery in adult patients. J Surg Res 2021; 260:28–37.
Wang LY, Roman BR, Migliacci JC, et al. Cost-effectiveness analysis of papillary thyroid cancer surveillance. Cancer 2015; 121:4132–4140.
Blefari NDA, Rowe CW, Wiadji E, et al. Long-term health-related quality of life outcomes following thyroid surgery for malignant or benign disease: deficits persist in cancer survivors beyond five years. World J Surg 2022; 46:2423–2432.
Applewhite MK, James BC, Kaplan SP, et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J Surg 2016; 40:551–561.
Goswami S, Mongelli M, Peipert BJ, et al. Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. Surgery 2018; 164:986–992.
Seok JH, Choi WJ, Lee YS, et al. Relationship between negative mental adjustment to cancer and distress in thyroid cancer patients. Yonsei Med J 2013; 54:658–664.
Broekhuis JM, Li C, Chen HW, et al. Patient-reported financial burden in thyroid cancer. J Surg Res 2021; 266:160–167.
Barrows CE, Belle JM, Fleishman A, et al. Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors. Surgery 2020; 167:378–384.
Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among thyroid cancer survivors. Surgery 2020; 167:631–637.
Blinder VS, Gany FM. Impact of Cancer on Employment. J Clin Oncol 2019; 38:302–308.
Araque DVP, Bleyer A, Brito JP. Thyroid cancer in adolescents and young adults. Future Oncol 2017; 13:1253–1261.
Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011; 103:117–128.
Boltz MM, Hollenbeak CS, Schaefer E, et al. Attributable costs of differentiated thyroid cancer in the elderly Medicare population. Surgery 2013; 154:1363–1370.
Peppercorn J. The financial burden of cancer care: do patients in the US know what to expect? Expert Rev Pharmacoecon Outcomes Res 2014; 14:835–842.
Greenup RA. Financial toxicity and shared decision making in oncology. Surg Oncol Clin N Am 2022; 31:1–7.